Key result
End-stage renal disease patients receiving hemodialysis had markedly higher plasma levels of omentin compared to healthy controls (606.6 vs 357.5 ng/ml; p < 0.0001).
Why the study?
Are plasma levels of omentin elevated in patients with end-stage renal disease receiving hemodialysis compared to healthy controls?
Case-Control (n=87)
Are plasma levels of omentin elevated in patients with end-stage renal disease receiving hemodialysis compared to healthy controls?
Absolute Event Rate: 606.6% vs 357.5%
p-value: p=< 0.0001
Plasma levels of the adipokine omentin are significantly elevated in patients with end-stage renal disease receiving hemodialysis and correlate with creatinine levels.
Elevated omentin in hemodialysis patients may mark altered adipokine status; leaves open any prognostic role in ESRD pending validation.
INTRODUCTION: Cardiovascular disease is the leading cause of morbidity and mortality in hemodialysis patients. Therefore, evaluation and prevention of cardiovascular diseases in end-stage renal disease (ESRD) patients are very important. The plasma level of omentin was found to be associated with different conditions such as insulin resistance. It is one of the novel adipokines synthesized mainly in the visceral adipose tissue. In this study, we aimed to investigate the level of omentin in patients with ESRD receiving hemodialysis. METHODS: The study population consisted of 59 adult chronic hemodialysis patients (30 women and 29 men) and age-matched control subjects were selected from apparently healthy subjects (28 participants; 14 women and 14 men). Blood samples were obtained before the dialysis session. Omentin concentrations were determined by using enzyme-linked immunosorbent assay. RESULTS: Plasma levels of omentin were found to be markedly higher in ESRD patients (606.6 ± 313.0 ng/ml) than in the control group (357.5 ± 147.4 ng/ml; p < 0.0001). Also, serum omentin levels were found to be correlated with creatinine (r = 0.333, p = 0.002). CONCLUSIONS: Omentin levels were found to be elevated in patients with ESRD receiving hemodialysis. To the best of our knowledge, this is the first clinical study that demonstrated the association between omentin and ESRD.
No takes yet. Share an insight, caveat, or question.
Alçelik et al. (2012) conducted a case-control in End-Stage Renal Disease (ESRD) (n=87). End-Stage Renal Disease (ESRD) requiring hemodialysis vs. Apparently healthy subjects was evaluated on Plasma levels of omentin (p=< 0.0001). End-stage renal disease patients receiving hemodialysis had markedly higher plasma levels of omentin compared to healthy controls (606.6 vs 357.5 ng/ml; p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: